|
[1] WANG H, JIA JD. Natural history and long-term outcome of chronic hepatitis B virus infection[J]. J Capit Med Univ,2010, 31(5):582-585.(in Chinese）王慧，贾继东．慢性HBV感染自然史及治疗对转归的影响[J]．首都医科大学学报，2010, 31(5):582-585.
|
|
[2] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int, 2016, 10(1):1-98.
|
|
[3] TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4):1560-1599.
|
|
[4] LAMPERTICO P, AJARWAL K, BERG T, et al. EASL 2017clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398.
|
|
[5] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019,35(12):2648-2669.(in Chinese）中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南（2019年版）[J]．临床肝胆病杂志，2019, 35(12):2648-2669.
|
|
[6] PAPATHEODORIDIS GV, MANOLAKOPOULOS S, LIAW YF,et al. Follow-up and indications for liver biopsy in HBeAgnegative chronic hepatitis B virus infection with persistently normal ALT:A systematic review[J]. J Hepatol, 2012, 57(1):196-202.
|
|
[7] WONG GL, CHAN HL, YU Z, et al. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B:A prospective cohort study with paired transient elastography examination[J]. J Gastroenterol Hepatol, 2013, 28(12):1842-1848.
|
|
[8] DIALLO I, NDIAYE B, FALL CA, et al. Inactive hepatitis B carriers:Outcomes of patients followed at Ho^pital Principal de Dakar, Senegal[J]. Pan Afr Med J, 2018, 31:49.
|
|
[9] TONG MJ, TRIEU J. Hepatitis B inactive carriers:Clinical course and outcomes[J]. J Dig Dis, 2013, 14(6):311-317.
|
|
[10] ZHANG S, SUN J, XING HC, et al. Progress on clinical cure of chronic hepatitis B[J/CD]. Chin J Liver Dis(Electronic Edition), 2018, 10(4):60-64.(in Chinese）张珊，孙静，邢卉春，等．慢性乙型肝炎临床治愈研究进展[J/CD]．中国肝脏病杂志（电子版），2018, 10(4):60-64.
|
|
[11] HABERSETZER F, MOENNE-LOCCOZ R, MEYER N, et al.Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection[J]. Liver Int,2015, 35(1):130-139.
|
|
[12] YEO YH, HO HJ, YANG HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection:A systematic review and meta-analysis[J]. Gastroenterology, 2019, 156(3):635-646.
|
|
[13] CHEN L, SHI J, LU Z, et al. Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase[J].Clin Res Hepatol Gastroenterol, 2019, 43(3):310-316.
|
|
[14] SAIFUDING MSSFDMS, SONG X, REZIWANGULI ABDL, et al.Effect of entecavir and telbivudine on chronic hepatitis B and renal function[J]. Chin J Med Offic, 2018, 46(9):1095-1096.(in Chinese）赛福丁·木沙赛福丁·木沙，宋雪，热孜万古丽·阿布都拉，等．恩替卡韦与替比夫定治疗慢性乙型肝炎有效性及对肾功能影响研究[J]．临床军医杂志，2018, 46(9):1095-1096.
|
|
[15] TENNEY DJ, ROSE RE, BALDICK CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy[J].Hepatology, 2009, 49(5):1503-1514.
|
|
[16] KWON JH, SONG MJ, JANG JW, et al. Efficacy and safety of tenofovir disoproxil fumarate in treatment-naïve patients with chronic hepatitis B in Korea[J]. Dig Dis Sci, 2019, 64(7):2039-2048.
|
|
[17] BUTI M, TSAI N, PETERSEN J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2015, 60(5):1457-1464.
|
|
[18] ZHANG H, CHAO J, ZHU L, et al. Direct economic burden and influencing factors in patients with hepatitis B virus related diseases in Jiangsu, China[J]. Asia Pac J Public Health,2015, 27(2 Suppl):41s-48s.
|
|
[19] ZHANG S, MA Q, LIANG S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China[J]. J Viral Hepat, 2016, 23(3):202-210.
|
|
[20] LIU ZH. The timing of antiviral therapy in chronic HBV patients with normal ALT and positive HBV DNA[J]. Nanning:Guangxi Medical University, 2015.(in Chinese）刘志红．ALT正常HBV DNA阳性的慢性HBV感染者抗病毒治疗时机的探讨[D]．南宁：广西医科大学，2015.
|
|
[21] CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2):435-444.
|
|
[22] ZHENG B, ZHU YJ, WANG HY, et al. Gender disparity in hepatocellular carcinoma(HCC):Multiple underlying mechanisms[J]. Sci China Life Sci, 2017, 60(6):575-584.
|
|
[23] RUGGIERI A, GAGLIARDI MC, ANTICOLI S. Sex-dependent outcome of hepatitis B and C viruses infections:Synergy of sex hormones and immune responses?[J]. Front Immunol,2018, 9:2302.
|
|
[24] TURATI F, EDEFONTI V, TALAMINI R, et al. Family history of liver cancer and hepatocellular carcinoma[J]. Hepatology,2012, 55(5):1416-1425.
|
|
[25] LIU X, BAECKER A, WU M, et al. Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population[J]. Liver Int, 2019, 39(8):1490-1503.
|
|
[26] HUANG G, LAU WY, ZHOU WP, et al. Prediction of hepatocellular carcinoma recurrence in patients with low hepatitis B virus DNA levels and high preoperative hepatitis B surface antigen levels[J]. JAMA Surg, 2014, 149(6):519-527.
|
|
[27] TSENG TC, LIU CJ, YANG HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads[J]. Hepatology, 2013, 57(2):441-450.
|
|
[28] TSENG TC, LIU CJ, YANG HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load[J]. Gastroenterology, 2012, 142(5):1140-1149.
|
|
[29] CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2):215-226.
|
|
[30] NAKAZAWA T, SHIBUYA A, TAKEUCHI A, et al. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels[J]. J Viral Hepat, 2011, 18(7):e191-e199.
|
|
[31] CHAO DT, LIM JK, AYOUB WS, et al. Systematic review with meta-analysis:The proportion of chronic hepatitis B patients with normal alanine transaminase≤40 IU/L and significant hepatic fibrosis[J]. Aliment Pharmacol Ther, 2014, 39(4):349-358.
|
|
[32] BAI XX, DONG B, GAO HY, et al. Clinical features of immune escape phase and immune control phase of chronic HBV infection[J]. J Clin Hepatol, 2018, 34(12):2568-2571.(in Chinese）白萧萧，东冰，高红艳，等．慢性HBV感染者免疫逃逸期与免疫控制期的临床特征分析[J]．临床肝胆病杂志，2018, 34(12):2568-2571.
|
|
[33] WANG H, RU GQ, YAN R, et al. Histologic disease in Chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels[J]. J Clin Gastroenterol,2016, 50(9):790-796.
|
|
[34] TSENG KC, CHEN CY, TSAI HW, et al. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase:Randomized, double-blind, placebocontrolled study[J]. Antivir Ther, 2014, 19(8):755-764.
|
|
[35] YAN JY, LI ZQ, YU ZJ, et al. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels[J]. J Cell Biochem,2019, 120(4):6632-6641.
|
|
[36] HOAN JK, YANG HI, LE A, et al. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis[J]. Medicine(Baltimore), 2016, 95(31):e4433.
|
|
[37] CHEN C, ZHUANG H. Epidemiological status of chronic hepatitis B in China[J]. Liver Doctor, 2018, 1:8-9.(in Chinese）陈词，庄辉．中国慢性乙肝流行病学现状[J]．肝博士，2018,1:8-9.
|
|
[38] CHU CM, LIAW YF. Natural history of hepatitis B virus infection[M]∥LIAW YF, ZOULIM F. Hepatitis B virus in human diseases. USA:Humana Press, 2016:217-247.
|
|
[39] CHEN JD, YANG HI, ILOEJE UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death[J]. Gastroenterology, 2010, 138(5):1747-1754.
|
DownLoad: